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In Brief
Loss of retinoblastoma protein (RB1) is
common in various difficult-to-treat
cancers. Cook et al. show that RB1 loss
significantly impairs repair of DNA via
non-homologous end-joining (NHEJ) and,
in doing so, promotes genomic instability.
These unexpected findings present
opportunities for future cancer therapies
that exploit this repair defect.
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Deficiencies in DNA double-strand break (DSB)
repair lead to genetic instability, a recognized cause
of cancer initiation and evolution. We report that the
retinoblastoma tumor suppressor protein (RB1) is
required for DNA DSB repair by canonical non-
homologous end-joining (cNHEJ). Support of cNHEJ
involves a mechanism independent of RB1’s cell-
cycle function and depends on its amino terminal
domain with which it binds to NHEJ components
XRCC5 and XRCC6. Cells with engineered loss of
RB family function as well as cancer-derived cells
with mutational RB1 loss show substantially reduced
levels of cNHEJ. RB1 variants disabled for the inter-
action with XRCC5 and XRCC6, including a cancer-
associated variant, are unable to support cNHEJ
despite being able to confer cell-cycle control. Our
data identify RB1 loss as a candidate driver of struc-
tural genomic instability and a causative factor for
cancer somatic heterogeneity and evolution.INTRODUCTION
DNA double-strand breaks (DSBs), where both strands of DNA
are severed, pose an exceptional threat to the stability of a cell’s
genome. DSBs are caused by reactive adducts produced during
normal metabolic reactions or following exposure to environ-
mental genotoxins, including radiation. Inability to repair DSBs
leads to DNA fragmentation and cell death. Unfaithful repair re-
sults in genetic instability (GIN) where cells may survive but chro-
mosomes become rearranged, and genetic material mutated,
duplicated, or deleted (Negrini et al., 2010).
GIN is a defining characteristic of cancer (Schmitt et al., 2012)
promoting initiation and somatic evolution, in turn, linking to dis-
ease progression and therapy resistance. To identify molecular
events that cause GIN is an important goal in cancer research.2006 Cell Reports 10, 2006–2018, March 31, 2015 ª2015 The AuthorDSBs can be repaired by two mechanistically distinct path-
ways, homologous recombination (HR) (Heyer et al., 2010) and
canonical non-homologous end-joining (cNHEJ) (Lieber, 2010).
HR involves single-strand resection of the damaged DNA with
re-synthesis that relies on the presence of a homologous sister
chromatid. cNHEJ effectively re-joins the severed DNA ends,
functioning in the absence of a homologous template. Because
cNHEJ has provision to trim DNA ends, it can repair breaks
where DNA is chemically modified and complex damage with
multiple close-by strand breaks, impeding the use of HR.
Although cNHEJ has reduced accuracy compared to HR, most
specifically when mending breaks that require end trimming,
repair by cNHEJ is conservative as gene positioning and
sequence co-linearity within chromosomes are strictly main-
tained and its simplicity and versatility make it the most promi-
nent route by which DSBs are repaired in higher eukaryotes.
cNHEJ also serves other roles, including VDJ recombination in
immune cells and telomere maintenance (reviewed in Doksani
and de Lange [2014] and Malu et al. [2012]).
Inhibition or mutational loss of cNHEJ or HR leads to use of
alternative, inaccurate forms of end-joining (aNHEJ), reliant on
resection that exposes serendipitous homology to adjacently
positioned yet often noncontiguous chromatin that then is
used as a template for repair (reviewed in Aparicio et al.
[2014]). Chromosomal alterations are thus generated, including
base changes, inversions, translocations, and deletions, with
consequence of code alteration, gene gain, loss or deregulation,
and the generation of gene fusions. Paired with mitotic check-
point defects, such misrepair may give rise to progressive GIN.
How canonical HR andNHEJ suppress the use of aNHEJ is not
clear. Answers most likely lie in the recruitment of accessory fac-
tors by the respective core repair machineries, which protect and
manage regulated access to the damaged DNA. These include a
diverse collection of chromatin modifying enzymes, comprising
effectors of protein acetylation, methylation, and ubiquitination,
as well as effectors of chromatin conformation, including the
imitation switch (ISWI) chromatin remodeling complexes and
the inhibitor of resection 53BP1 (reviewed in Panier and Boulton
[2014] and Papamichos-Chronakis and Peterson [2013]).s
The retinoblastoma protein (RB1) is an important tumor sup-
pressor. Mutational loss of RB1 is implicated in the develop-
ment of the childhood eye cancer retinoblastoma but also
major cancers including breast and small cell lung cancer,
sarcomas, and glioblastoma. Germline mutations in the RB1
encoding gene are associated with a highly penetrant predispo-
sition to retinoblastoma (Lohmann, 2010) and substantially in-
crease the lifetime risk for a spectrum of secondary cancers
(Meadows et al., 2009). RB1 belongs to a family of proteins
with similar molecular anatomy and related function. RB1 and
its paralogs are best recognized for their role in the control of
gene transcription by which they affect the cell cycle and a
range of other responses, including cell differentiation, epithelial
to mesenchymal transition, angiogenesis, cell migration, and
metabolism (reviewed in Schaal et al. [2014]). More recently
other roles of RB1 have been uncovered, fully or partially inde-
pendent of its role in controlling gene transcription or the cell
cycle, including the activation of apoptosis through association
with the cell’s mitochondria (Hilgendorf et al., 2013) and in the
control of mitotic fidelity (reviewed in Manning and Dyson
[2012]). The latter indicates a key contribution of RB1 in safe-
guarding numerical chromosomal stability and points to RB1
loss as the cause of aneuploidies observed in cancers with
RB1 involvement.
Genomic analysis of retinoblastoma, a cancer that virtually
always involves RB1 loss, identified widespread GIN, signified
by extensive gain and loss of subchromosomal regions
(reviewed in The´riault et al. [2014]), in addition to numerical
chromosome abnormalities in a portion of these cancers. These
observations suggest RB1 loss, in addition to numerical chro-
mosome instability, may affect chromosome integrity, leading
to GIN.
Here, we report that the RB family proteins are required for
repair of DNA by cNHEJ. We show that these proteins through
use of their amino-terminal domains associate with the core
components XRCC5 and 6 of the cNHEJ damage recognition
machinery. Our work identifies RB1 and its paralogs as critical
factors in cNHEJ with roles of suppressing the use of alternative,
inaccurate end-joining in cells. The work identifies RB1 loss as a
plausible cause of GIN in cancers with RB1 loss.
RESULTS
Interaction between RB1N and Components Involved
in NHEJ
RB1 is built from two major folded domains, the central pocket
domain, RB1P, and the amino-terminal domain, RB1N (Hensey
et al., 1994), that between them share similarities including fold
analogy and conservation of isostructural surfaces (Hassler
et al., 2007). RB1P is recognized for its ability to interact with
key cellular proteins, including members of the E2 factor (E2F)
family of transcription factors and proteins containing an Leu-
X-Cys-X-Glu (LXCXE) linear motif (Lee et al., 1998, 2002; Xiao
et al., 2003), through which RB1 confers transcriptional regula-
tion, cell-cycle regulation, and tumor suppression (reviewed in
Schaal et al. [2014]). The mode of action of RB1N has not been
mechanistically defined, although 20% of identified frame-
preserving tumor mutations reside in this domain, and deletionCellresults in tumor development in mice, predicting importance of
this domain in tumor suppression (Goodrich, 2003).
Owing to the structural similarity of RB1N and RB1P, we
reasoned that RB1N, like RB1P, may act by binding partner pro-
teins and that identification of these will reveal the functional sig-
nificance of RB1N. To capture partner proteins, we utilized as a
matrix glutathione S-transferase (GST)-tagged RB1 40-355
(RB1N), previously employed to determine the structure of this
domain (Hassler et al., 2007), together with HeLa nuclear extract,
and liquid chromatography-tandem mass spectrometry (LC-
MS/MS) for partner protein identification. We performed parallel
experiments using purified GST tag to distinguish proteins
selectively captured by RB1N, which identified 34 proteins that
selectively interacted with RB1N (Table S1; Supplemental Exper-
imental Procedures).
Mining for associations of these proteins with cellular pro-
cesses using the Database for Annotation, Visualization and In-
tegrated Discovery (DAVID) (Dennis et al., 2003) uncovered a
number of ontologies enriched in representation by the list of in-
teracting proteins compared to the nuclear proteome (Fig-
ure 1A), among them ‘‘DNA double-strand repair via NHEJ’’
and related ontologies, suggesting a connection between RB1
and NHEJ. In particular, XRCC5 (Ku80), XRCC6 (Ku70), and
PRKDC (DNA-PK), required for DSB repair by cNHEJ (Lieber
et al., 2003), were identified with high confidence (Table S1).
Subsequent affinity capture using extract from two other cell
lines, HCT116 colon and MCF-7 breast cancer cells, combined
with antibody-based detection of XRCC5 and XRCC6 (Figures
1B and 1C) confirmed selective retention of these proteins by
GST-RB1N.
It has been reported that XRCC5 and XRCC6 can be contam-
inants associated with affinity-capture experiments (Mellacher-
uvu et al., 2013). To gain additional evidence for the selectivity
of the observed interactions, we made use of a RB1N variant
(RB1NPolyG) with a fold-preserving alteration in the B cyclin
wedge, predicted by analogy to support protein binding (Figures
1D and 1E) (Hassler et al., 2007). While XRCC6 was readily
recovered from HCT116 lysate by wild-type GST-RB1N (Fig-
ure 1C), only a minor amount of XRCC6 was recovered using
GST-RB1NPolyG (Figure 1F). Identical results were obtained using
RB1N240–242 del, a cancer-associated RB1 variant (Shuin et al.,
1995) featuring a three amino acid deletion in the same region
(Figures 1D and 1G). Together, these experiments provide
strong evidence for selectivity of the interactions. They further
identify a specific RB1N region, predicted to confer protein bind-
ing (Hassler et al., 2007), as responsible for mediating the inter-
action with XRCC5 and XRCC6.
To document that these interactions arise with cell endoge-
nous components, we immunoprecipitated RB1 from cells (Fig-
ure 1H). We used asynchronously growing HCT116 cells or
HCT116 cells treated with the CDK4/6 selective inhibitor
PD0332991, which enriches for G1 phase cells with underphos-
phorylated, active RB1 (Fry et al., 2004), followed by ionizing
radiation (IR), to induce DSB damage. These experiments
confirmed XRCC5 and XRCC6 associate with RB1 and further
revealed an increased amount of XRCC5 and XRCC6 is recov-
ered under conditions of RB1 activation and DNA damage, sug-
gesting regulation of the interaction.Reports 10, 2006–2018, March 31, 2015 ª2015 The Authors 2007
Figure 1. Interaction between RB1N and
NHEJ Proteins
(A) Graph depicting enrichment scores calculated
using the DAVID gene annotation tool (biological
processes). Proteins selectively captured by
GST-RB1N (amino acids 40–355) were scored
against a self-generated nuclear proteome back-
ground. The ontologies shown are represented by
three or more proteins with >10-fold enrichment
over background.
(B and C) Affinity capture on GST RB1N with
analysis by immunoblotting. Nuclear extracts
derived from MCF-7 (B) or HCT116 (C).
(D) Schematic representation of full-length RB1
(top) and the folded RB1N (bottom). The position of
the twin cyclin-like folds building the scaffold
of RB1N and RB1P are indicated. The location
of residue alterations yielding RB1NPolyG and
RB1N240–242 deletion is indicated.
(E) Ribbon diagram representation of the structure
of RB1N (adapted from Hassler et al. [2007]); the
unoccupied cyclin wedge region is denoted with a
circle, the location of the PolyG alteration is
indicated by a dotted line, and the position of
RB1N240–242 deletion is denoted in red.
(F) GST-affinity capture using HCT116 cell lysate
with GST, RB1N, or RB1NPolyG.
(G) GST-affinity capture using HCT116 cell lysate
with GST, RB1N, or RB1N240–242 deletion.
(H) Co-immunoprecipitation of cell endogenous
XRCC5 and XRCC6 with RB1 from HCT116. Cells
were left untreated or treated with a CDK4/6
selective inhibitor of RB1 phosphorylation
PD0332991 (400 nM for 18 hr) followed by irradi-
ation at 5 Gy (IR), with extract preparation 30 min
post IR. RAM, irrelevant control antiserum; RB1C,
anti-RB1C domain antiserum; In., input lysate.Regulation of the Interaction between XRCC6 and RB1
To further confirm RB1/XRCC5/XRCC6 complexes exist within
intact cells, we employed proximity ligation (PLA), which visual-
izes protein interactions in fixed cells based on antibody-medi-
ated detection of the respective interaction partners (Weibrecht
et al., 2010). We probed for the interaction between RB1 and
XRCC6 in both MCF-7 (Figures 2A and 2B) and HCT116 cells
(Figure S1B), which were untreated or treated with PD0332991
or IR alone or in combination. To document assay selectivity,
we ablated RB1 using small interfering RNA (siRNA) (Figure 2D;
Figures S1A, S1D, and S1E) or omitted one or both primary
antibodies (Figures S1F and S1G). These experiments confirmed2008 Cell Reports 10, 2006–2018, March 31, 2015 ª2015 The Authorscomplexes between XRCC6 and RB1
exist in cells, and that these were located
in the cell nucleus.
A notable and statistically significant in-
crease in both complex abundance and
the number of complex-positive cells
was observed when cells were pre-
treated with PD0332991 followed by IR.
Greater than 60% of either MCF-7 or
HCT116 cells treated in this way con-
tained six or more foci compared to20%–25% treated with PD0332991 or IR alone, and <15%of un-
treated cells (Figures 2B, S1F, and S1G; statistics in Table S2).
Immunoblotting confirmed loss of RB1 phosphorylation in
PD0332991-treated cells (Figure 2C). Notably, differences
in interaction seen by PLA were not paralleled by differences in
the levels of XRCC5, XRCC6, or RB1 in the cells, excluding pro-
tein abundance changes as the cause for the increase in interac-
tions. We also assessed MCF-7 and HCT116 cells enriched for
mid-S or G2/M phase alongside cells enriched for G1 using
PD0332991. Flow cytometry confirmed appropriate cell-cycle
distributions (Figures 2G and S2E). We observed absence of
foci in the vast majority of mid-S and G2/M-enriched cells but
Figure 2. Regulation of the Interaction be-
tween XRCC6 and RB1 in Cells
(A) PLA probing for XRCC6/RB1 complex inMCF-7
cells. Cells were left untreated or treated with the
PD0332991 (400 nM for 18 hr), IR (5 Gy) or
PD0332991 (400 nM for 18 hr) followed by IR
(5 Gy). Cells were analyzed 30 min post IR. Nuclei
visualized with Hoechst 33258. Parallel staining in
the absence of primary or secondary antibodies
shown in Figure S2A. Identical experiments using
HCT116 shown in Figure S1B.
(B) Automated quantification of PLA foci. Data
represent counts for a minimum of 100 cells per
condition from n = 3 biological repeats. The per-
centage of cells for each range of interactions is
shown. For statistical assessment of results, see
Table S2.
(C) Immunoblotting analysis of P-Ser780 RB1,
serving as a biomarker for CDK4/6 activity. XRCC5
and XRCC6 and RB1 total protein levels were also
assessed. Actin levels are shown as loading
controls.
(D) PLA probing for XRCC6/RB1 complex in
MCF-7 cells treated with non-targeting (siNT) or
RB1 targeting siRNA. Cells were treated with
PD0332991 followed by 5 Gy IR as described for
(A). For parallel anti-RB1 staining, see Figure S1A.
Identical experiments using HCT116 shown in
Figures S1D and S1E.
(E) Detection of RB1/XRCC6 complex in cell-cycle-
phase-enriched cells. Cells were enriched for the
various cell-cycle phases as depicted in Fig-
ure S2A. XRCC6/RB1 complexes were detected
using PLA. Related data for HCT116 are shown in
Figure S2.
(F) Automated quantification of foci number.
Cumulative data for n = 3 biological replicates are
shown. Data represent evaluation of a minimum of
100 independent cells. Quantification was per-
formed as for (B).
(G) Cell-cycle profiles of the cells analyzed in (E),
determined by propidium iodide staining and flow
cytometry. Error bars represent ± SD for n = 3
biological replicates.
(H) Immunoblotting analysis depicting protein
levels of RB1, XRCC5, and XRCC6 in cells en-
riched for the various cell-cycle phases. Actin
levels are shown as loading controls.presence of foci in many of the G1 enriched cells (Figures 2E–2H
and S2; statistics in Table S3). Likewise, these differences were
not paralleled by altered abundance of RB1, XRCC5, or XRCC6
(Figures 2H and S2C). Together, these results provide additional
evidence for complex formation between the NHEJ components
and RB1, which appears to be promoted by RB1 activation
and DSBs, in line with our earlier observations using RB1
immunoprecipitation.
RB Family Proteins Promote PRKDC-Dependent NHEJ
Since different methodologies confirmed the interaction of RB1
with components involved in cNHEJ, we assessed whether
RB1 affects NHEJ activity in cells. To do so, we used a reporter
(Bennardo et al., 2008) (Figure 3A) in which a removable puromy-Cellcin-resistance gene is inserted between the GFP reading frame
and its promoter. I-SceI expression in cells induces removal of
the insertion, leaving a DSB that when repaired by NHEJ leads
to GFP expression (GFP+), allowing quantification of repair pro-
ficiency by flow cytometry. We quantified NHEJ proficiency in
HCT116 cells in which siRNA was used to deplete RB1 either
alone or together with its paralogs RBL1/p107 and RBL2/p130,
known to act redundantly with RB1 in many cell types (Henley
and Dick, 2012). To identify cells with reporter uptake, we co-
transfected plasmid encoding red fluorescent protein (DsRed).
RB1 depletion led to a significant reduction in NHEJ proficiency
(Figures 3B and 3C) that was further augmented by co-depletion
of RBL1 and RBL2 (Figure 3C), confirming a redundant role of the
RB paralogs in NHEJ in HCT116. Cell-cycle analysis performedReports 10, 2006–2018, March 31, 2015 ª2015 The Authors 2009
Figure 3. RB Family Proteins Promote
PRKDC-Dependent NHEJ
(A and B) Reporter-based quantification of NHEJ
repair. Cells were transfected with NHEJ reporter
and I-SceI encoding plasmid to introduce DSBs,
with repair by NHEJ yielding GFP-positive cells (A).
DsRed was used to identify transfected cells.
Assays were quantified using flow cytometry.
Representative raw images for HCT116 cells
treated with siRNA targeting RB1 or RB1, RBL1,
and RBL2, or a non-targeting control (siNT) are
shown (B) NHEJ repair proficiency is determined
by calculating the ratio of GFP-positive (Q2) versus
DsRed-positive cell (Q1 + Q2).
(C) Graph depicting repair proficiency in NHEJ re-
porter-transfected cells. Cells were treated as for
(B). NHEJ repair proficiency for cells transfected
with siNT was set to 1. Binding of XRCC5 by RBL1
and RBL2 shown in Figure S3.
(D) Cell-cycle profiles for DsRed-positive cells
from (C).
(E) Effect of PRKDC inhibition on reporter repair
proficiency. HCT116 cells were treated and eval-
uated as for (C). DMSO or the PRKDC inhibitor
NU7441 (5 mM) was added for the duration of the
experiment.
(F) Immunodetection documenting RB1 and RB
protein family loss in HCT116. HCT116 transfected
with siRNA as in (C)–(E). Lysates probed using
antibodies as indicated.
(G) NHEJ proficiency in SAOS-2 (RB1-negative)
and U2OS (RB1-positive) cells using transient
NHEJ reporter transfection as for (C) and (D).
(H) Effect of PRKDC inhibition on NHEJ profi-
ciency. SAOS-2 and U2OS cells with integrated
NHEJ reporter were used. Lines were transfected
with I-SceI and DsRed plasmids and treated with
DMSO or NU7441 as for (E). For all experiments,
the average for n = 3 biological replicates is de-
picted; error bars ±SD. *p < 0.05, **p < 0.01, ***p <
0.001 using a paired Student’s t test.
(I) Immunodetection of PRKDC-Ser2056 phos-
phorylationstatus.AutophosphorylationofPRKDC-
Ser2056 signifies PRKDC activity. Cells were
treated with 5 mMNU7441 for 24 hr prior to 5 Gy IR.
2 hr post IR, the cells were harvested into SDS
protein loading buffer. Actin and total PRKDC levels
are shown as loading controls.in parallel for DsRed+ cells of the various treatment groups de-
tected no statistically significant differences, indicating that
functional RB loss in these cells, within the time frame and
manipulations undertaken, does not cause overt cell-cycle dif-
ferences (Figure 3D). Hence, cell-cycle differences are not the
cause of the difference in reporter repair proficiency that we
detect.
Since our functional analysis indicates RBL1 and/or RBL2 act
redundantly to RB1 in NHEJ, we sought to address whether
these RB1 paralogs interact with NHEJ components, as
observed for RB1. Using GST-fused fragments of RBL1 and
RBL2 homologous to RB1N together with HCT116 nuclear
extract, we performed affinity-capture experiments as for Fig-
ure 1, with control reactions containing GST-RB1N or unfused
GST (Figure S3). These experiments clearly document selective2010 Cell Reports 10, 2006–2018, March 31, 2015 ª2015 The Authorcapture of XRCC5 by RBL1 and RBL2 arising with comparable
efficacy to that seen for RB1 (Figure S3B).
The NHEJ reporter used measures cNHEJ as well as some
portion of aNHEJ that is independent of PRKDC (Chiruvella
et al., 2013). To distinguish between these different forms
of NHEJ repair, we treated reporter-transfected cells with
NU7441, a PRKDC inhibitor, which prevents cNHEJ (Zhao
et al., 2006). We found that NU7441 reduced NHEJ reporter ac-
tivity significantly (p < 0.01) in control cells but not in cells with
ablation of RB family proteins (Figure 3E). This data provide
strong evidence that repair reduction following RB family protein
depletion results from loss of cNHEJ with the detected residual
reporter activity arising from PRKDC-independent repair.
To probewhether cNHEJ is affected in cancerswithmutational
RB1 loss, we assessed reporter repair in SAOS-2 osteosarcomas
cells, which carry an inactivating mutation in RB1 (Hellwinkel
et al., 2005) and U2OS osteosarcoma cells, which have wild-
type RB1. Using transient reporter transfections, SAOS-2 cells
displayed a significantly lower level of NHEJ capacity (Figure 3G)
compared to U2OS cells. We further used SAOS-2 and U2OS
lines with stable chromosomal integration of the NHEJ reporter,
assessing their respective propensity to undertake PRKDC-
dependent, NU7441-sensitive repair. NU7441 did not affect
repair proficiency in SAOS-2 cells but significantly reduced repair
proficiency in theU2OScells (Figure 3H). These experiments pro-
vide direct evidence for diminished use of cNHEJ in RB1mutated
cancer cells. They in addition confirm repair loss is observable in
chromosomally integrated, chromatinized settings. Immunoblot-
ting for PRKDC autophosphorylation (Ser2056) indicated that
NU7441 achieved PRKDC inhibition in HCT116, SAOS-2, and
U2OS cells (Figure 3I). This analysis further reveals activation of
PRKDC occurs in SAOS-2, indicating that PRKDC activation,
an early step of cNHEJ repair, arises independently of RB1
function.
The Role of RB1N in NHEJ
To test whether re-expression of RB1 reinstates the capacity of
RB1-negative cells to perform cNHEJ, we transfected plasmid
encoding human RB1 (Chew et al., 1998) alongside the NHEJ re-
porter into SAOS-2 cells. We also transfected these cells with
plasmid encoding the PolyG alteration shown in our earlier ex-
periments (see Figures 1D and 1E) to disable the interaction
with XRCC6. Expression of RB1 significantly increased NHEJ
competency compared to vector transfection. In contrast,
RB1PolyG was unable to increase NHEJ proficiency (Figure 4A).
Furthermore, expression of RB1 but not expression of RB1PolyG
restored sensitivity of repair to NU7741, supporting that RB1 but
not RB1PolyG reinstates use of cNHEJ in the transfected cells.
Parallel immunoblotting revealed equal expression of RB1 and
RB1PolyG (Figure 4C). Identical results also were obtained with
the XRCC6 binding-defective cancer-associated variant,
RB1240–242 del (Figure S4), which like RB1PolyGwas unable to sup-
port NHEJ despite appropriate expression. RB1 strongly in-
hibited cell-cycle progression in the transfected SAOS-2 cells,
promoting their accumulation and stable arrest in G1 (Figure 4B).
This is an expected outcome for RB1-negative cancer cells,
where transformation associated hyperactivation of the INK4/
ARF locus prevents cell-cycle-dependent RB1 inactivation,
and contrasts to cancer and primary cells containing wild-type
(WT) RB1 expression that usually are competent to inactivate
RB1 (Hinds et al., 1992). Significantly, cell-cycle arrest was
seen also where RB1PolyG (Figure 4B) and RB1240–242 del (Fig-
ure S4B) were used, with no statistically significant difference
detectable compared with RB1. These results provide direct ev-
idence that enablement of cNHEJ by RB1 is not an attribute, or
consequence, of G1 cell-cycle arrest, which can be actioned
by NHEJ-competent WT RB1 and the NHEJ-incompetent
variants alike, but involves a mechanism distinct and geneti-
cally separable from that involved in cell-cycle control. This
conclusion is supported further by experiments run under
conditions that did not involve DNA damage reporter co-
expression, revealing identical potency of RB1, RB1PolyG, and
RB1240–242 del to support G1 cell-cycle arrest and E2F regulationCelland to suppress colony outgrowth of SAOS-2 cells (Figures 4D–
4H and S4D–S4H).
The described observations in SAOS-2 were also corrobo-
rated by experiments using mouse embryo fibroblasts (MEFs)
with disruption of RB1, RBL1, and RBL2 (TKOs) (Dannenberg
et al., 2000). Expression of RB1 significantly increased NHEJ
competency, while RB1PolyG, despite adequate expression, did
not (Figures 4I and 4L). In these cells, no significant impact on
cell-cycle distribution or the ability to progress through the cell
cycle to G2 was detected upon expression of either wild-type
RB1 or RB1PolyG, in keeping with the ability of these primary cells
to undertake cell-cycle-dependent RB1 inactivation, providing
further emphasis that the differential support of NHEJ is not ex-
plained by differential effects of the two RB1 forms on the cell cy-
cle and is not relying on dominant cell-cycle arrest instilled by
RB1 (Figure 4K). In summary, these results provide strong evi-
dence for a role of RB1 in supporting cNHEJ. They further docu-
ment a mechanism of action distinct from RB1’s function of con-
trolling cell-cycle progression and reveal selective loss of ability
to support NHEJ in RB1 variants defective for XRCC5 and
XRCC6 binding, including a naturally occurring cancer-associ-
ated variant.
RB Family Protein Loss Impairs DNA Damage Clearance
Loss of cNHEJ in cells leads to use of alternative, slower forms of
repair, resulting in reduced speed by which DSBs are resolved
(Kinashi et al., 2011; Vandersickel et al., 2010). We therefore
determined whether repair speed was reduced by RB1 loss us-
ing TKO MEFs as well as congenic MEFs with disruption in RB1
(RB1/) (Jacks et al., 1992), measuring loss of gH2AX foci as a
surrogate for the DSBs resolution (Kuo and Yang, 2008)
(Figure 5A).
Automated high-content image analysis (Figures 5B–5D) re-
vealed a delay in gH2AX signal loss detectable within 2 hr post
IR, indicative of reduced repair speed in both these genetic
backgrounds within a time frame comparable to that reported
for cells with XRCC5 and XRCC6 loss (Kinashi et al., 2011; Van-
dersickel et al., 2010). Furthermore, repair delay was exagger-
ated in TKO compared to RB1/MEFs, consistent with our pre-
vious observations documenting exacerbated repair loss in
HCT116 with combined loss of RB paralogs (Figure 3). Quantifi-
cation of cells with residual damage confirmed significantly
reduced gH2AX clearance in MEFs with RB1 or RB family loss
(Figure 5C). Similar levels of gH2AX fluorescence were observed
early (15 min) after exposure to IR in all MEF lines, indicating that
differences in gH2AX signals at later time points do not reflect a
difference in the amount of initial damage (Figure 5C).
The speed by which DSBs are repaired is dependent on cell-
cycle position (Chapman et al., 2012). To address whether the
differences in repair proficiency observed could be due to differ-
ences in the cell-cycle distribution between the different MEF
lines, we measured the DNA content by integrating the intensity
of the Hoechst DNA stain in the same cells that were quantified
for gH2AX intensity. Histograms generated from these measure-
ments revealed typical cell-cycle profiles (Figure S5), but no sig-
nificant differences in the overall cell-cycle distributions between
backgrounds in any of the three experiments as assessed byWil-
coxon rank-sum testing. Similarly, t testing following gating forReports 10, 2006–2018, March 31, 2015 ª2015 The Authors 2011
Figure 4. The Role of RB1N in NHEJ
(A) NHEJ proficiency in SAOS-2 cells expressing
RB1 or RB1PolyG variant and response to NU7441
treatment. Data evaluation was as for Figure 3.
Related data for RB1240–242 deletion are shown in
Figure S4.
(B) Cell-cycle profiles for cells transfected along-
side cells from (A). Nocodazole was added 16 hr
before harvest to quantify stable G1 arrest.
(C) Immunodetection of RB1 and RB1PolyG in
SAOS-2 from (A); loading was normalized for co-
transfected DsRed expression plasmid.
(D) Proficiency of RB1PolyG to inhibit cell-cycle
progression in SAOS-2. Graph depict percentage
of cells with stable G1 arrest, assessed as in (B).
SAOS-2 cells transfected with empty vector, RB1,
or Poly G expression vector. Related data for
RB1240–242 deletion are shown in Figure S4.
(E) Proficiency of RB1PolyG to inhibit colony for-
mation. SAOS-2 transfected with empty RB1 or
RB1PolyG encoding vector in combination with
vector for puromycin resistance and scored
for outgrowth of puromycin resistant colonies.
Co-transfected b-galactosidase was used to
normalize data to transfection efficacy. Related
data for RB1240–242 deletion are shown in Figure S4.
(F) Proficiency of RB1PolyG to regulate E2F activity.
E2F reporter activity in SAOS-2 cells. Cells were
transfected with RB1, RB1PolyG, or empty expres-
sion vector together with E2F promoter luciferase
reporter. Co-transfectedb-galactosidasewasused
to normalize data to transfection efficacy. Related
data for RB1240–242 deletion are shown in Figure S4.
(G) Immunodetection of RB1 and RB1PolyG in
SAOS-2used in (D)and (E).Loadingwasnormalized
using co-transfected EGFP expression plasmid.
(H) Immunodetection of RB1 and RB1PolyG in
SAOS-2 used in (F). Loading was normalized to
b-galactosidase activity.
For all experiments the average for n = 3 biological
replicates is depicted; error bars ± SD. *p < 0.05,
**p < 0.01, ***p < 0.001 using a paired Student’s
t test.
(I) NHEJ proficiency in TKO MEFs transfected with
empty vector or vector expressing RB1 or
RB1PolyG variant. Data evaluation was as for (A).
Values for MEFs transfected with empty vector
were set to 1.
(J) Cell-cycle profiles of reporter transfected TKO MEFs, analyzed as for Figure 4I. Profiles with or without secondary nocodazole block are shown. Data
represent transfected cell fractions deduced using DsRed for gating.
(K) Immunodetection of RB1 and RB1PolyG in MEFs from (I); loading was normalized for co-transfected DsRed expression plasmid.cells with <2n, 2n, >2–4n, and >4n DNA content (Figure S5) re-
vealed no statistically significant difference for any of these
categories at any of the observed time points, ruling out overt
cell-cycle variations as an explanation for the differences in
DSB clearance observed.
Effect of RB Protein Loss in the Maintenance of
Chromosomal Integrity
To obtain direct evidence that RBprotein loss impairs DNA repair
and assess whether RB protein loss adversely affects chromo-
somal integrity as expected for cells with cNHEJ defect (Iliakis
et al., 2004), we determined chromatin repair and chromosomal
radiation sensitivity using comet analysis and metaphase2012 Cell Reports 10, 2006–2018, March 31, 2015 ª2015 The Authorspreads (Figure 6). Comet analysis detected a significant in-
crease in cells with excess unligated chromatin, detectable as
late as 8 hr after irradiation in cells with RB family loss. Similar re-
sults were obtained for TKO MEFs compared to WT MEF and
HCT116 in which RB family proteins were depleted using siRNA
compared to either mock-treated HCT116 or HCT116 treated
with a nontargeting oligonucelotide (Figure 6; for raw data, see
Figure S6). No significant difference was observed in the amount
or distribution of DNA damage immediately after irradiation, indi-
cating defective DNA repair as opposed to increased damage
susceptibility in cells with RB family loss. We also assessed radi-
ation-induced excess first division chromosomal aberrations,
initially using HCT116 cells with siRNA-mediated RB familys
Figure 5. RB Family Protein Loss Impairs
DNA Damage Clearance
(A) DSB clearance in cells with compromised RB1
function. Wild-type, RB1/, or RB1/RBL1/RBL2-
null (TKOs) mouse embryonic fibroblasts (MEFs)
were exposed to IR of 5 Gy. Prevalence of damage
at the indicated times was detected by immuno-
fluorescence staining for gH2AX (green); nuclei
were visualized with Hoechst 33258 (blue). Raw
images recorded using a high-content imaging
platform are shown. Scale bar represents 10 mm.
(B and C) Automated quantitative assessment of
damage clearance. gH2AX staining intensity (iSig)
was determined for all cells from 30 independent
eye fields. (B) Integrated H2AX signal distribution
for cells from one representative experiment. The
dotted line shows the gating position for cells with
above baseline anti-gH2AX fluorescence. DNA
content analysis for the same samples shown in
Figure S5. (C) Percentage of cells with residual
damage determined by gating (dotted line) for cells
with above baseline anti-gH2AX fluorescence at
each time point. Error bars represent ±SD for n = 3
biological replicates. *p < 0.05, **p < 0.01, ***p <
0.001 using a paired Student’s t test comparing
RB1/ or TKOs to wild-type cells.
(D) Immunodetection documenting RB protein
family loss in MEFs. Lysate from MEFs used for
(A)–(C) were probed using antibodies as indicated.loss. We observed a significant increase in the frequency of
chromosomal aberrations compared to mock-transfected cells,
comprised of increased chromosome-type aberrations and sur-
plus chromatid breaks (Table S4). Identical results were obtained
when we treated these same cells with siRNA targeting DNA
ligase 4 (LIG4), involved in DNA strand ligation in cNHEJ. We
also probed for loss of chromosomal integrity in irradiated TKO
MEFs, revealing a consistent and significant increase of chromo-
some-type aberrations compared to congenic wild-type MEFs
(Figure S6; Table S4). Together these results strongly support
the notion that loss of RB function significantly impairs cellular
DSB repair and significantly increases the incidence of structural
chromosomal aberrations and chromosomal instability.
DISCUSSION
We here document a thus-far-unrecognized role of the RB
family in supporting DNA repair by cNHEJ. We show that RBCell Reports 10, 2006–2018family protein loss is associated with
canonical features observed in cells with
defective cNHEJ, including loss of
PRKDC-dependent damage repair, de-
layed damage clearance, and excess
genotoxin-induced structural chromo-
somal aberrations.
Loss of cNHEJ promotes chromosomal
rearrangements presumed to arise from
increased use of error-prone aNHEJ
(Rothkamm et al., 2003). Our experiments
documenting delayed repair kinetics andexcess same cycle chromosomal aberrations in cells with RB
family protein loss is consistent with this notion. We note that
the excess of chromosomal aberrations is more pronounced
and diverse in transformed HCT116 cells compared to primary
MEFs. Differences in type and level of chromosomal aberrations
between primary and transformed cells with cNHEJ loss have
been noted previously (Burma et al., 2006) andmay be explained
by loss of DNA integrity surveillance in cancers cells, permitting
survival and cell-cycle progression despite reduced repair.
A substantial body of recent work has documented loss of
mitotic fidelity in cellular models with RB1 loss (Manning and
Dyson, 2012) and loss of mitotic fidelity is well suited to explain
the development of chromosomal aneuploidy seen in retinoblas-
toma tumors. However, loss of mitotic fidelity cannot explain the
spectrum of GIN seen in retinoblastoma. Genomic profiling of
malignant retinoblastoma compared to premalignant retinoma
lesions suggests complex GIN is associated with malignant pro-
gression in this disease (Dimaras et al., 2008; Sampieri et al.,, March 31, 2015 ª2015 The Authors 2013
Figure 6. RB Family Loss Impairs Break Repair and Increases Radiation Induced Chromosomal Aberration
(A) Analysis of DNA strand break induction and repair by Comet assay. Data for wild-type and RB family defective (TKO) MEFs and data for HCT116 colorectal
cancer cells transfected with siRNA targeting RB family proteins RB1, RBL1, and RBL2, a non-targeting control (NT), or in the absence of oligonucleotide are
(legend continued on next page)
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2008) andGIN, comprising extensive copy-number changes and
rearrangements, is prominent in late onset, sporadic disease,
with presence in early onset, familial cases, although to a lesser
degree (The´riault et al., 2014). These observations identify GIN
as a relevant, albeit facultative event in retinoblastoma progres-
sion consistent with a concept whereby defective repair
following from RB1 loss combines with stochastic factors,
including environmental genotoxin exposure and checkpoint
loss, that cooperate to unleash GIN in this disease. Significantly,
recent work documented excess micronuclei formation, indica-
tive of excess acentric chromosome fragments, in primary
murine osteoblasts with RB1 loss, exacerbated by IR (Gonza-
lez-Vasconcellos et al., 2013), which is in agreement with our
observations of excess genetic aberration in cells with loss of
RB function. Importantly, evidence of excess chromosomal
aberrations was apparent in cells with heterozygous loss of
RB1, inferring systemic repair defects may manifest in individ-
uals with constitutional RB1 mutation where heterozygous de-
fects are present in somatic tissue. Defective DSB repair with
excess genotoxin-driven genetic aberration documented here
and in Gonzalez-Vasconcellos et al. (2013) may explain the
recognized risk for secondary cancers in such patients following
external beam radiotherapy and genotoxic chemotherapy, for
which a mechanistic justification has thus far been lacking (Klei-
nerman et al., 2012; Wong et al., 2014).
Our data allow us to draw several mechanistic conclusions
pertaining to the contribution of RB1 to cNHEJ. We identify
two different fold-preserving variants affecting RB1N that are
defective for the interaction with XRCC6. Significantly, we docu-
ment that these RB1 variants are unable to support NHEJ in pri-
mary MEFs with RB family loss and in cancer-derived SAOS-2
osteosarcoma cells with spontaneous inactivation of RB1.
Together these results provide strong support that the physical
interaction with cNHEJ proteins underlies the mechanism
through which RB1 affects this form of repair. Importantly, RB1
variants defective in supporting NHEJ were capable of blocking
cell-cycle progression and E2F transcriptional activation as
effectively as WT RB1, providing strong support that neither
loss of cell-cycle inhibition nor loss of E2F regulation provide a
mechanistic explanation for the contribution of RB proteins in
NHEJ that we describe. A recent report demonstrates stimula-
tion of HR following enforced expression of RB1 in a RB1-
mutated, retinoblastoma-derived cell line, which could suggest
a potentially broader role of RB1 in DSB repair (Yang et al.,
2013). Whether RB1 has a direct critical role in HR or whether
cell-cycle changes seen to arise in the cells following RB1
expression indirectly affected repair pathway choice is not
known. HR components were not identified in the mass spec-shown. Cells were treated with either 10 or 15 Gy and harvested for analysis at t
technical replicates. 25 cells per replicate were analyzed.
(B) Immunodetection documenting RB protein family loss in MEFs and HCT11
Figure S6 and probed using antibodies as indicated.
(C) Chromosome aberration analysis. HCT116 treated with siRNA as for (A) were
IR. Colcemid was added for the final 10 hr. Table S4 provides full numerical detai
MEFs shown in Figure S6.
(D) Examples of Giemsa-stained metaphases, documenting aberrations detect
documenting exemplary aberration scored. Aberrations denoted by arrows; dc,
Error shown represents SEM. *p < 0.05, **p < 0.01, ***p < 0.001 using an unpaire
Celltrometry approach we used suggesting the mechanistic contri-
bution of RB1 to NHEJ and HR is distinct. As noted DSB repair
involves extensive chromatin modification. RB1 and its paralogs
can facilitate chromatin modification through recruitment of
chromatin modifiers that mostly interact with RB1P and the
RB1 carboxyterminal region (reviewed in Manning and Dyson
[2012] and Talluri and Dick [2012]). Intriguingly, several of
these modifiers are known to be involved in cNHEJ, including
the ISWI remodeling machine (Aydin et al., 2014), the HDAC1
and 2 histone deacetylases (Miller et al., 2010), the SUV4 histone
methyl transferase (Tuzon et al., 2014), and the inhibitor of
resection 53BP1 (Carr et al., 2014). A proposition for a mecha-
nism of action how RB family proteins support cNHEJ could be
that they, by way of interaction with the damage recognition
complex, recruit these chromatin modifiers to the site of DNA
repair.
A considerable body of evidence supports the view that
cNHEJ is active and hasmajor roles during G1 and early S (Bran-
zei and Foiani, 2008), the cell-cycle phases where RB family
proteins are naturally active or are known to be activated by
DNA damage-associated inhibition of the CDK4, 6, and 2
cyclin-dependent kinases. Recent work has shown that cNHEJ
is also used in G2 (Kakarougkas and Jeggo, 2014), where RB
proteins are not known to be active. Our quantitative data based
on monitoring reporter repair argue the contribution of RB family
proteins is considerable, with little PRKDC-dependent repair ac-
tivity observed in cells with RB loss. However, G2 phase cells are
naturally underrepresented in actively proliferating cell popula-
tions. Hence, the quantitative contribution of G2 cells to the total
repair activity within the population is expected to be small and
may remain underreported by the reporter-based assessment
used here.
NHEJ plays a key role in VDJ recombination, and mutations in
components of cNHEJ, including PRKDC and Artemis, result in
severe combined immunodeficiency (SCID) affecting B and
T cell maturation in humans and mice (Woodbine et al., 2014).
While there is evidence that mechanistic differences between
DSB repair and VDJ exist (Malu et al., 2012), it is possible that
RB1 loss alone or together with its paralogs affects VDJ recom-
bination in addition to DSB repair. Homozygous loss of RB1 is
embryonic lethal in mice (Jacks et al., 1992) and presumably in
human. RB1 loss arises in individuals with somatic or germline
heterozygous mutations upon subsequent loss of the wild-type
allele through secondary mutation or mitotic nondisjunction.
Given the rarity of these events, it would not be expected that
VDJ deficiency and associated pathologies are observable, or
clinically relevant, in this context. However, several studies
have assessed the effect of engineered RB1 and RB familyhe indicated time. Data shown are derived from two independently processed
6. Lysates were prepared from MEFs and HCT116 used for (A), (C), (D), and
irradiated with the dose indicated. Cells were processed for analysis 16 hr post
ls of all analyses. Errors represent SEM. Related analysis of wild-type and TKO
ed in HCT116. Examples of Giemsa-stained metaphases from HCT116 cells
dicentric; ac, excess acentric fragment; ctb, chromatid break.
d heteroscedacstic Student’s t test.
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deletion on the hematopoietic system in the mouse (Daria et al.,
2008; Viatour et al., 2008; Walkley and Orkin, 2006). Although
these studies did not explicitly address whether VDJ recombina-
tion is lost, phenotypes consistent with such loss were observed.
Two independent studies examining RB1 deletion note a consid-
erable decrease in B cells with IGG/IGM rearrangement,
although the number of B cells precursors with un-rearrange
IGG/IGM was not unaltered (Daria et al., 2008; Walkley and
Orkin, 2006). No effect on T cell maturation was observed, which
might be explained by redundant functioning of RB family pro-
teins in this lineage. Radical loss of common lymphoid precur-
sors was observed following combined deletion of the RB family
(Viatour et al., 2008), indicating additional and profound early
lineage reliance on RB family proteins at a stage predating
T cell differentiation and VDJ recombination, precluding conclu-
sions as to the role of the RB family in VDJ recombination in this
lineage.
Our experiments document that the role of RB1 in cNHEJ in-
volves the RB1N domain. Although a role of RB1N in tumor sup-
pression had been anticipated (Blanquet et al., 1995; Lee et al.,
1992; Lohmann et al., 1997), a mechanistic basis of how defects
in this region contribute to cancer development has remained
elusive. This work now demonstrates a defined functional role
of this domain. The involvement of RB1N in supporting cNHEJ
provides a plausible mechanistic explanation for tumorigenicity
associated with mutations in this region.
Our results have important conceptual implications in that they
identify RB family proteins as cofactors supporting cNHEJ and
predict impairment of this repair pathway in RB1-negative can-
cers with consequence of structural chromosomal instability
that promotes tumor evolution in response to genotoxic stress.
They also present potential opportunities for therapy that exploit
the greater reliance of such cancers on alternative routes of
repair.
EXPERIMENTAL PROCEDURES
Cells, DNA plasmids, siRNA, and antibodies and general procedures involving
these are described in the Supplemental Experimental Procedures.
GST Affinity Capture and Mass Spectrometry
GST fusion proteins were expressed in E. coli and produced as described
(Hassler et al., 2007). Purified GST tagged proteins were bound to Glutathione
Sepharose 4 Fast Flow resin and used as an affinity matrix for interacting pro-
tein capture from nuclear cell extract. Affinity-captured proteins were either
assessed using tryptic proteolysis followed by MS analysis (QSTAR Elite,
Applied Biosystems) or immunoblotting. Raw MS data were analyzed using
Mascot version 2.1 (Matrix Science) followed by Scaffold 3 (Proteome
Software).
Co-immunoprecipitation
Nuclear extracts were prepared from purified cell nuclei using micrococcal
nuclease to release chromatin-bound protein complexes. Cell nuclei were
made as for GST affinity capture. RB1 was immunoprecipitated using rabbit
serum against a human RB1 C-terminal fragment (aa 763–928) (Zarkowska
and Mittnacht, 1997) crosslinked to Protein A/G Plus Agarose (Thermo Fisher
Scientific).
Proximity Ligation Analysis
PLA was performed using Duolink technology (Cambridge Biosciences) in
accordance with the manufacturer’s recommendations.2016 Cell Reports 10, 2006–2018, March 31, 2015 ª2015 The AuthorgH2AX Staining and Quantitation
Cells were cultured in black-walled 96-well plates (PerkinElmer) and fixed and
processed as described in Richardson et al. (2012). Cells were probed with
anti-gH2AX for 3 hr at room temperature followed by Alexa Fluor 488 fluores-
cent secondary antibody (Invitrogen) containing 2 mMHoechst 33342 (Sigma).
Plates were imaged using an automated high-content platform (GE Health-
care). The average intensity (iSig) of the gH2AX signal was recorded for all
individual cells present in six eye fields in each of five wells. The integrated in-
tensity for Hoechst 33342 was extracted using CellProfiler Image analysis
freeware.
NHEJ Reporter Assay
NHEJ reporter assays were performed as described (Bennardo et al., 2008).
For parallel cell-cycle analysis NHEJ reporter/DsRed-transfected cells were
subjected to fluorescence-activated cell sorting for DsRed-positive cells.
DsRed-positive cells were subjected to propidium iodide (PI) staining of
DNA followed by analysis using flow cytometry. Alternatively, transfected cells
were subjected to life-cell staining of DNA using Hoechst 33342 dye. Prior to
analysis cells were incubated for 45 min in media containing 10 mg/ml Hoechst
33342 followed by dual color flow cytometry analysis with data collection
gated for DsRed-positive cells. Data for 5,000–10,000 individual cells were
collected in each case.
Cell-based assays assessing the effect of RB1 on E2F regulation and cell
proliferation are described in the Supplemental Experimental Procedures.
Chromosomal Radiation Sensitivity Analysis
HCT116 cells were transfected with siRNA 48 hr prior to irradiation. Colcemid
(Sigma-Aldrich Karyomax) was added at 20 ng/ml 6 hr (HCT116) or 24 hr
(MEFs) post IR. Cells were harvested for analysis 16 hr (HCT116) or 28 hr
(MEFs) post IR using trypsin. Giemsa-stained metaphase spreads were pre-
pared and analyzed as previously described (Nuta et al., 2014).
Comet Analysis
Cells irradiated on ice were either harvested immediately (0 hr) or following
further incubation at 37C. Cells were embedded in low melting agarose on
glass slides followed by lysis in 100 mM EDTA, 2.5 M NaCl, 10 mM Tris-HCl
(pH 10.5), 1% Triton X-100 followed by electrophoresis in 50 mM NaOH,
1 mM disodium EDTA (pH 12.5). Slides were stained with propidium iodide,
visualized at 203 magnification, and analyzed using Komet Analysis software
6.0 (Andor Technology).
Additional details for all experimental procedures are provided in the Sup-
plemental Experimental Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
six figures, and four tables and can be found with this article online at http://
dx.doi.org/10.1016/j.celrep.2015.02.059.
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